MONTREAL, June 10, 2013 /CNW Telbec/ - As a proud sponsor for 18 years now of the Bourse Fernand-Seguin, one of Canada's most prestigious fellowships for scientific journalism, Merck would like to offer heartfelt congratulations to this year's recipients.
Anabel Cossette Civitella was awarded the Bourse Fernand-Seguin by jury members for her article entitled "Machine cherche cerveau" [Machine Seeking Brain]. Looking at the interaction between brain and machine to develop thought-controlled devices, her article explains an innovation that would circumvent paralysis. The 23-year-old author majors in international development and minors in psychology. She will be awarded a $12,000 bursary along with a six-month internship in scientific journalism.
"The Bourse Fernand-Seguin is a major stepping stone for young science communicators in Québec, who play an important role in disseminating new discoveries and popularizing the scientific issues of today and tomorrow," says Jennifer Chan, Vice President, Policy and Communications at Merck Canada. "Merck is proud to be associated with the emergence of these new talents in science writing."
"The Bourse Fernand-Seguin is a monument of scientific culture in Québec, and Merck has been part of this long tradition through its support for emerging talent in science journalism year after year," says Binh An Vu Van, President of the Association des communicateurs scientifiques du Québec. "Its ongoing contribution has made the company one of the pillars of the bursary. As a science journalist, I am also pleased to see that Merck, a major player in the pharmaceutical industry, understands the value of quality science journalism and has spent years taking an interest in and supporting it, and pursuing a dialogue with associations like ours."
Merck Canada is committed to supporting young people who share its enthusiasm for research and scientific progress through various projects, such as the Science Fairs, which it has been supporting for more than 20 years, and the Bourse Fernand-Seguin. The company firmly believes in its commitment to the community. Merck's contribution to the Bourse Fernand-Seguin is a natural extension of its efforts to raise public awareness about science.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information about our operations in Canada, visit www.merck.ca.
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
SOURCE: Merck Canada Inc.
For further information: